
FHI Clinical Inc. providing clinical operations services for ACTT-1 trial of remdesivir for treatment of COVID-19
July 14, 2020
FHI Clinical Inc. announced that it has a subcontract with the Frederick National Laboratory for Cancer Research, currently operated by Leidos Biomedical Research, Inc., to provide clinical operations services for the Adaptive COVID-19 Treatment Trial (ACTT). ACTT is an adaptive study to allow investigation of putative therapeutics, for the treatment of COVID-19 in hospitalized adults.